Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy.
暂无分享,去创建一个
M. Gleave | A. Wyatt | M. Annala | K. Chi | G. Vandekerkhove | M. Zulfiqar | K. Sunderland | D. Khalaf | J. Vergidis | D. Finch | K. Beja | C. Oja